Dr. Barry Greenberg
Board Member
Advisory Board
Neurodyn
Canada
Biography
Barry Greenberg has been involved in Alzheimer’s disease research and drug discovery since 1985. He has held a series of positions internationally in the US, Sweden and Canada within the biotechnology and pharmaceutical industries. Before joining University Health Network (UHN) as Director, Neuroscience Drug Discovery and Development, he was Senior Director of Pharmacology at Neurochem, where he was responsible for the preclinical biology research program and contributor to the analyses of the phase III Alzhemed trial. He is also co-directing, as Director of Strategy for the Toronto Dementia Research Alliance at UHN, a consortium involving academic research and the five memory clinics at hospitals affiliated with the University of Toronto to create a citywide dementia research center. He possesses a significant background in most aspects of the drug discovery process in neurological disease, with externally recognized expertise ranging from target identification and validation through preclinical and clinical development including issues of biomarker-based diagnosis. He has a strong international network in the Alzheimer field including industry, academia, government and the voluntary sector, plus previous involvement in multi-sector consortia, and was recently a member of the committee charged with drafting the scientific strategic recommendations to inform the National Alzheimer Plan in the US.. He has authored or co-authored 70 articles in peer-reviewed journals and 19 book chapters and reviews.
Research Interest
Pharmacology
